{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:23:13Z","timestamp":1792452193694,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["U1249"],"award-info":[{"award-number":["U1249"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007353","name":"Fondation J\u00e9r\u00f4me Lejeune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001673","name":"Fondation J\u00e9r\u00f4me Lejeune","doi-asserted-by":"publisher","award":["PNRR\\u2013 M4 C2 I1.1 -PRIN 2022CZTZ87- CUP F53D23006660006"],"award-info":[{"award-number":["PNRR\\u2013 M4 C2 I1.1 -PRIN 2022CZTZ87- CUP F53D23006660006"]}],"id":[{"id":"10.13039\/501100001673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001673","name":"Fondation J\u00e9r\u00f4me Lejeune","doi-asserted-by":"publisher","award":["2209 \\u2013 GRT-2023A"],"award-info":[{"award-number":["2209 \\u2013 GRT-2023A"]}],"id":[{"id":"10.13039\/501100001673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020320","name":"IReSP","doi-asserted-by":"publisher","award":["IReSP-AAPSPS2022-V3-05"],"award-info":[{"award-number":["IReSP-AAPSPS2022-V3-05"]}],"id":[{"id":"10.13039\/501100020320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["M4-C2-Inv"],"award-info":[{"award-number":["M4-C2-Inv"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["IReSP-AAPSPS2022-V3-05"],"award-info":[{"award-number":["IReSP-AAPSPS2022-V3-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA043982"],"award-info":[{"award-number":["R01DA043982"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1.5 -CUP F83B22000040006"],"award-info":[{"award-number":["1.5 -CUP F83B22000040006"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.tips.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:07:13Z","timestamp":1737378433000},"page":"145-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders"],"prefix":"10.1016","volume":"46","author":[{"given":"Olivier J.","family":"Manzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Manduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-6045","authenticated-orcid":false,"given":"Viviana","family":"Trezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2024.12.005_bb0005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1124\/pharmrev.122.000600","article-title":"Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years","volume":"75","author":"Maccarrone","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2024.12.005_bb0010","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: similarities and differences between siblings","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2024.12.005_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114347","article-title":"A scoping review of the use of cannabidiol in psychiatric disorders","volume":"308","author":"Kirkland","year":"2022","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0020","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1124\/pharmrev.123.001121","article-title":"The development of cannabinoids as therapeutic agents in the United States","volume":"76","author":"Murray","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2024.12.005_bb0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bcp.14973","article-title":"A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans","volume":"88","author":"Arout","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s42238-024-00222-2","article-title":"A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders","volume":"6","author":"Omotayo","year":"2024","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.tips.2024.12.005_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s41061-024-00465-w","article-title":"Unraveling the mechanisms of cannabidiol's pharmacological actions: a comprehensive research overview","volume":"382","author":"Kalsoom","year":"2024","journal-title":"Top. Curr. Chem. (Cham)"},{"key":"10.1016\/j.tips.2024.12.005_bb0045","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11095-023-03469-1","article-title":"Cannabidiol for the treatment of brain disorders: therapeutic potential and routes of administration","volume":"40","author":"Yau","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/bs.irn.2024.05.001","article-title":"Cannabidiol: pharmacodynamics and pharmacokinetic in the context of neuropsychiatric disorders","volume":"177","author":"Lirio","year":"2024","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.tips.2024.12.005_bb0055","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3390\/biom12101462","article-title":"Sex differences in the neuropsychiatric effects and pharmacokinetics of cannabidiol: a scoping review","volume":"12","author":"Matheson","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.tips.2024.12.005_bb0060","doi-asserted-by":"crossref","first-page":"e1170","DOI":"10.1089\/can.2022.0345","article-title":"Sex differences in the pharmacokinetics of cannabidiol and metabolites following oral administration of a cannabidiol-dominant cannabis oil in healthy adults","volume":"9","author":"MacNair","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0065","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0070","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/j.pain.0000000000001386","article-title":"Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain","volume":"160","author":"De Gregorio","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.tips.2024.12.005_bb0075","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.109.162594","article-title":"The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes","volume":"333","author":"Yang","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2024.12.005_bb0080","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0085","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.tips.2024.12.005_bb0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tips.2024.12.005_bb0100","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0105","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.3390\/molecules26092456","article-title":"Allosteric modulation of the CB1 cannabinoid receptor by cannabidiol-A molecular modeling study of the N-terminal domain and the allosteric-orthosteric coupling","volume":"26","author":"Jakowiecki","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2024.12.005_bb0110","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0115","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2024.12.005_bb0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tips.2008.12.004","article-title":"The enigmatic pharmacology of GPR55","volume":"30","author":"Ross","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2024.12.005_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0130","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2024.12.005_bb0135","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1089\/can.2021.0041","article-title":"Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting","volume":"6","author":"Rock","year":"2021","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA(A) receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1042\/NS20200080","article-title":"Cannabidiol modulation of oxidative stress and signalling","volume":"5","author":"Pereira","year":"2021","journal-title":"Neuronal Signal."},{"key":"10.1016\/j.tips.2024.12.005_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106603","article-title":"Cannabinoid-mediated targeting of mitochondria on the modulation of mitochondrial function and dynamics","volume":"187","author":"Malheiro","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154771","article-title":"Cannabidiol goes nuclear: the role of PPARgamma","volume":"114","author":"Khosropoor","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.tips.2024.12.005_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2024.12.005_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105092","article-title":"Cannabidiol counters the effects of a dominant-negative pathogenic Kv7.2 variant","volume":"25","author":"Zhan","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.tips.2024.12.005_bb0170","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/19336950.2019.1615824","article-title":"Cannabinoid interactions with ion channels and receptors","volume":"13","author":"Watkins","year":"2019","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.tips.2024.12.005_bb0175","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","article-title":"Inhibitory effects of cannabidiol on voltage-dependent sodium currents","volume":"293","author":"Ghovanloo","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2024.12.005_bb0180","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.1074\/jbc.M707104200","article-title":"Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol","volume":"283","author":"Ross","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2024.12.005_bb0185","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic cyp450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tips.2024.12.005_bb0190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/03602532.2024.2346767","article-title":"Effects of cannabidiol and Delta(9)-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review","volume":"56","author":"Smith","year":"2024","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.tips.2024.12.005_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108948","article-title":"Cannabidiol and substance use disorder: dream or reality","volume":"207","author":"Karimi-Haghighi","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13150","article-title":"CBD-mediated regulation of heroin withdrawal-induced behavioural and molecular changes in mice","volume":"27","author":"Navarrete","year":"2022","journal-title":"Addict. Biol."},{"key":"10.1016\/j.tips.2024.12.005_bb0205","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tips.2024.12.005_bb0210","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1111\/bph.14226","article-title":"Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal","volume":"175","author":"Navarrete","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0215","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bph.14147","article-title":"Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice","volume":"176","author":"Myers","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0220","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881120965952","article-title":"Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice","volume":"35","author":"Calpe-Lopez","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110462","article-title":"CB1 receptor antagonist AM4113 reverts the effects of cannabidiol on cue and stress-induced reinstatement of cocaine-seeking behaviour in mice","volume":"113","author":"Lujan","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107740","article-title":"Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT(1A) and TRPV1 receptor mechanisms","volume":"167","author":"Galaj","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0235","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.euroneuro.2021.04.008","article-title":"Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats","volume":"50","author":"Metz","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0240","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0245","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1037\/pha0000272","article-title":"Effects of cannabidiol on alcohol-related outcomes: a review of preclinical and human research","volume":"27","author":"Nona","year":"2019","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106655","article-title":"Cannabidiol repairs behavioral and brain disturbances in a model of fetal alcohol spectrum disorder","volume":"188","author":"Gasparyan","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109829","article-title":"Oral cannabidiol does not alter alcohol seeking and self-administration in baboons","volume":"245","author":"Moore","year":"2023","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.tips.2024.12.005_bb0260","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbi.2018.11.003","article-title":"Anti-inflammatory agents for smoking cessation? Focus on cognitive deficits associated with nicotine withdrawal in male mice","volume":"75","author":"Saravia","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2024.12.005_bb0265","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00213-021-05845-4","article-title":"Cannabidiol reduces withdrawal symptoms in nicotine-dependent rats","volume":"238","author":"Smith","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0270","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tips.2024.12.005_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.694510","article-title":"Cannabidiol and Sertraline regulate behavioral and brain gene expression alterations in an animal model of PTSD","volume":"12","author":"Gasparyan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110508","article-title":"Early-life stress induces emotional and molecular alterations in female mice that are partially reversed by cannabidiol","volume":"115","author":"Martin-Sanchez","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0285","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41386-018-0282-7","article-title":"Delta-9-tetrahydrocannabinol and cannabidiol produce dissociable effects on prefrontal cortical executive function and regulation of affective behaviors","volume":"44","author":"Szkudlarek","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0290","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1523\/JNEUROSCI.0708-19.2019","article-title":"Cannabidiol counteracts the psychotropic side-effects of delta-9-tetrahydrocannabinol in the ventral hippocampus through bidirectional control of ERK1-2 phosphorylation","volume":"39","author":"Hudson","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2024.12.005_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110352","article-title":"Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum","volume":"111","author":"Pedrazzi","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2024.173879","article-title":"Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmission","volume":"245","author":"Pedrazzi","year":"2024","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2024.12.005_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104749","article-title":"Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors","volume":"156","author":"Rodrigues da Silva","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114004","article-title":"Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment","volume":"177","author":"Stark","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0315","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.bbi.2019.07.018","article-title":"Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders","volume":"81","author":"Osborne","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2024.12.005_bb0320","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00213-022-06196-4","article-title":"Cannabidiol for the treatment of autism spectrum disorder: hope or hype?","volume":"239","author":"Pedrazzi","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0325","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neubiorev.2020.12.009","article-title":"Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story","volume":"121","author":"Carbone","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2024.12.005_bb0330","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00787-023-02169-w","article-title":"Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review","volume":"33","author":"Rice","year":"2024","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0335","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2024.12.005_bb0340","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bph.15003","article-title":"Cannabidiol improves survival and behavioural co-morbidities of Dravet syndrome in mice","volume":"177","author":"Patra","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1359810","article-title":"Cannabidiol is a behavioral modulator in BTBR mouse model of idiopathic autism","volume":"18","author":"Shrader","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tips.2024.12.005_bb0350","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/ejn.16350","article-title":"Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5(R59X) knock-in mice","volume":"59","author":"Li","year":"2024","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.tips.2024.12.005_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107176","article-title":"Cannabidiol and positive effects on object recognition memory in an in vivo model of Fragile X syndrome: obligatory role of hippocampal GPR55 receptors","volume":"203","author":"Manduca","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1185737","article-title":"Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder","volume":"17","author":"Staben","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.tips.2024.12.005_bb0365","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41398-021-01612-3","article-title":"Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder","volume":"11","author":"Poleg","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107878","article-title":"Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder","volume":"226","author":"Zamberletti","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2024.12.005_bb0375","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled Trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0380","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0385","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41398-023-02410-9","article-title":"Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder","volume":"13","author":"Hua","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0390","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00213-022-06303-5","article-title":"Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder","volume":"240","author":"Lees","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0395","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","article-title":"Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study","volume":"43","author":"Meneses-Gaya","year":"2021","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0400","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/add.15417","article-title":"Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial","volume":"116","author":"Mongeau-Perusse","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.tips.2024.12.005_bb0405","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00213-023-06349-z","article-title":"Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol","volume":"240","author":"Karoly","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s42238-024-00250-y","article-title":"Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol","volume":"6","author":"Bhuller","year":"2024","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2019","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0420","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front. Psychol."},{"key":"10.1016\/j.tips.2024.12.005_bb0425","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease","volume":"34","author":"de Faria","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0430","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","article-title":"Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis","volume":"237","author":"Appiah-Kusi","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0435","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00213-022-06070-3","article-title":"The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study","volume":"239","author":"Bloomfield","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0440","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00213-023-06437-0","article-title":"The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo controlled trial","volume":"240","author":"Gournay","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial","volume":"59","author":"Kwee","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0450","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","article-title":"Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder","volume":"239","author":"Bolsoni","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0460","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0465","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0470","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/02698811211001107","article-title":"Cannabidiol modulation of hippocampal glutamate in early psychosis","volume":"35","author":"O'Neill","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0475","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1017\/S0033291719003519","article-title":"Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis","volume":"51","author":"O'Neill","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.tips.2024.12.005_bb0480","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jpsychires.2023.05.019","article-title":"The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder","volume":"163","author":"van Boxel","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0485","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1017\/S0033291723002775","article-title":"Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol","volume":"54","author":"Davies","year":"2024","journal-title":"Psychol. Med."},{"key":"10.1016\/j.tips.2024.12.005_bb0490","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41398-020-0862-2","article-title":"A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis","volume":"10","author":"Davies","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0495","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41398-019-0534-2","article-title":"Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis","volume":"9","author":"Wilson","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0500","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism."},{"key":"10.1016\/j.tips.2024.12.005_bb0505","article-title":"Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial","volume":"46","author":"Silva","year":"2024","journal-title":"Trends Psychiatry Psychother."},{"key":"10.1016\/j.tips.2024.12.005_bb0510","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD)","volume":"33","author":"Pretzsch","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0515","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder","volume":"44","author":"Pretzsch","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2024.12.005_bb0520","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","article-title":"A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)","volume":"14","author":"Berry-Kravis","year":"2022","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tips.2024.12.005_bb0525","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","article-title":"Cannabidiol adverse effects and toxicity","volume":"17","author":"Huestis","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.tips.2024.12.005_bb0530","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review","volume":"107","author":"Freeman","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2024.12.005_bb0535","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0540","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54752","article-title":"Assessment of orally administered delta9-tetrahydrocannabinol when coadministered with cannabidiol on delta9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: a randomized clinical trial","volume":"6","author":"Zamarripa","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.tips.2024.12.005_bb0545","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/cpt.3381","article-title":"Cannabidiol increases psychotropic effects and plasma concentrations of delta(9)-tetrahydrocannabinol without improving its analgesic properties","volume":"116","author":"Gorbenko","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tips.2024.12.005_bb0550","article-title":"Statement on safety of cannabidiol as a novel food: data gaps and uncertainties","volume":"20","author":"EFSA Panel on Nutrition, N.F","year":"2022","journal-title":"EFSA J."},{"key":"10.1016\/j.tips.2024.12.005_bb0555","author":"Food and Drug Administration"},{"key":"10.1016\/j.tips.2024.12.005_bb0560","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41398-022-02271-8","article-title":"In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner","volume":"12","author":"Iezzi","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2024.12.005_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106588","article-title":"Prenatal tetrahydrocannabinol and cannabidiol exposure produce sex-specific pathophysiological phenotypes in the adolescent prefrontal cortex and hippocampus","volume":"199","author":"DeVuono","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2024.12.005_bb0570","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/can.2021.0015","article-title":"Perinatal CBD or THC exposure results in lasting resistance to fluoxetine in the forced swim test: reversal by fatty acid amide hydrolase inhibition","volume":"7","author":"Maciel","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.tips.2024.12.005_bb0575","article-title":"Cannabidiol activates neuronal Kv7 channels","volume":"11","author":"Zhang","year":"2022","journal-title":"Elife"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724002712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724002712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:45:08Z","timestamp":1740401108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614724002712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0165614724002712"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2024.12.005","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}